Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 12/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.47 |
| ▸ | ESRRB | O95718 | 2/20 | 0.47 |
| ▸ | ESRRG | P62508 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081522 | 0.87 | ALDH1A1 (0.55) | MCHR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6080985 | 0.87 | MCHR1 (0.54) | MCHR1ESR1MAPK14CYP1A2CYP2D6 | |
| SCHEMBL6081903 | 0.87 | MCHR1 (0.54) | MCHR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6081331 | 0.86 | MCHR1 (0.53) | MCHR1ESR1MAPK14CYP1A2CYP2D6 | |
| SCHEMBL6081632 | 0.85 | MCHR1 (0.52) | MCHR1ESR1MAPK14CYP1A2CYP2D6 | |
| SCHEMBL6081460 | 0.84 | MCHR1 (0.49) | MCHR1ESR1MAPK14CYP1A2CYP2D6 | |
| SCHEMBL1728493 | 0.84 | MCHR1 (0.78) | MCHR1KCNH2 | |
| SCHEMBL6081954 | 0.84 | MCHR1 (0.49) | MCHR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1729490 | 0.84 | MAPK14 (0.56) | MCHR1MAPK14CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6081338 | 0.84 | MCHR1 (0.51) | MCHR1MAPK14CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1551810-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004012648-A2 | SUBSTITUTED DIARYL HETEROCYCLES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011438-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | MCHR1 1462/4885ESR1 3572/4885MAPK14 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.